



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31 MARCH 2015

Rs. in Lacs

Sr. No.	Particulars	Quarter Ended			Year Ended	
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
1	<b>Income from Operations</b>					
a	Net Sales / Income from operations (net of excise duty)	7482.74	6779.49	13063.80	38472.53	56350.13
b	Other Operating Income	44.58	16.34	34.97	129.86	128.87
	<b>Total income from Operations (net)</b>	<b>7527.32</b>	<b>6795.83</b>	<b>13098.77</b>	<b>38602.39</b>	<b>56479.00</b>
2	<b>Expenses</b>					
a	Cost of materials consumed	7150.79	5364.64	9133.17	30085.22	39791.52
b	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1125.22)	(40.10)	(631.22)	(2162.43)	(2799.02)
d	Employee benefits expense	574.04	608.03	722.64	2471.85	2707.70
e	Depreciation and amortisation expense	726.79	777.97	788.81	2891.05	3163.03
f	Other expenditure	1820.31	1888.74	1488.83	6951.76	7074.95
	<b>Total Expenses</b>	<b>9146.71</b>	<b>8599.28</b>	<b>11502.23</b>	<b>40237.45</b>	<b>49938.18</b>
3	Profit from Operations before Other Income, finance cost and Exceptional Items ( 1-2 )	(1619.39)	(1803.45)	1596.54	(1635.06)	6540.82
4	Other Income	0.45	0.45	0.45	1.80	1.80
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	(1618.94)	(1803.00)	1596.99	(1633.26)	6542.62
6	Finance costs	1474.75	1406.55	1499.20	5910.54	6034.39
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	(3093.69)	(3209.55)	97.79	(7543.80)	508.23
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	<b>Profit (+) / Loss (-) from ordinary activities before tax (7+8)</b>	<b>(3093.69)</b>	<b>(3209.55)</b>	<b>97.79</b>	<b>(7543.80)</b>	<b>508.23</b>
10	Tax Expense	(288.14)	(200.17)	16.76	(878.73)	178.29
11	<b>Net Profit (+)/Loss (-) from ordinary activities after tax (9-10)</b>	<b>(2805.55)</b>	<b>(3009.38)</b>	<b>81.03</b>	<b>(6665.07)</b>	<b>329.94</b>
12	Extraordinary Item (net of tax expense)					
13	Net Profit (+)/Loss (-) for the period (11-12)	(2805.55)	(3009.38)	81.03	(6665.07)	329.94
14	Paid-up equity share capital (Face value Rs. 10/- Per Share)	4765.55	4765.55	2881.52	4765.55	2881.52
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				15355.96	16042.49
16	Earning per share (before and after extraordinary item (Face value of Rs. 10/- each)					
	Basic	(6.38)	(7.88)	0.28	(16.72)	1.21
	Diluted	(6.97)	(7.56)	0.28	(16.63)	1.21
	Cash	(5.55)	(6.55)	3.01	(11.67)	13.11



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## PART-II SELECT INFORMATION FOR THE YEAR ENDED 31 MARCH 2015

Sr. No.	Particulars	Quarter Ended			Year Ended	Year Ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
<b>A</b>	<b>Particulars of Shareholding</b>					
1	Public Shareholding					
	- No of Shares	25218536	25256236	11776611	25218536	11776611
	-Percentage of Shareholding	52.92	53.00	40.87	52.92	40.87
2	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of shares		-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)					
	- Percentage of shares ( as a % of the total share capital of the company)					
	b) Non-encumbered					
	- Number of shares	22436966	22399266	17038553	22436966	17038553
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares ( as a % of the total share capital of the company)	47.08	47.00	59.13	47.08	59.13

B	Particulars	3 months ended 31 March 2015
		<b>Investor Complaints</b>
1	Pending at the beginning of the quarter	NIL
2	Received during the quarter	NIL
3	Disposed of during the quarter	NIL
4	Remaining unresolved at the end of the quarter	NIL



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## STATEMENT OF ASSETS AND LIABILITIES

Rs.in Lacs

S.NO.	PARTICULARS	As at 31.03.2015	As at 31.03.2014
		Audited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholder's Funds		
	(a) Share Capital	4765.55	4882.52
	(b) Reserves and Surplus	15355.96	16042.49
	(c) Money received against share warrants	598.50	-
	Sub-total - Shareholder's funds	20720.01	20925.01
2	Non current liabilities		
	a) Long term borrowings	27709.76	22041.05
	b) Deferred tax liabilities (net)	38.33	1213.88
	c) Other long term liabilities	808.88	2262.87
	d) Long term provisions	29.77	30.24
	Sub-total Non-current liabilities	28586.74	25548.04
2	Current liabilities		
	a) Short term borrowings	12044.33	9695.68
	b) Trade payables	7024.83	12035.52
	c) Other current liabilities	1781.12	5857.03
	d) Short term provisions	3.65	48.97
	Sub-total Current liabilities	20853.93	27637.20
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>70160.68</b>	<b>74110.25</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current assets		
	(a) Fixed assets	40702.84	44366.21
	(b) Non-current investments	4.00	-
	(c) Long term loans and advances	1076.22	1310.58
	(d) Other non-current assets	29.00	361.03
	sub-total non-current assets	41812.06	46037.82
2	Current assets		
	(a) Current investments	1.00	-
	(b) Inventories	21342.43	19222.61
	(c) Trade receivables	3267.19	4925.61
	(d) Cash and cash equivalents	1270.12	1144.75
	(e) Short- term loans and advances	2467.88	2779.46
	(f) Other current assets	-	-
	sub-total current assets	28348.62	28072.43
	<b>TOTAL ASSETS</b>	<b>70160.68</b>	<b>74110.25</b>



Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Pb.) India - CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India

Ph. : +91-1679 -285285-86. Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

Rs. in Lacs


Particulars	Quarter Ended			Year Ended	
	Unaudited	Unaudited	Unaudited	Audited	Audited
	31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
<b>1. Segment Revenue</b>					
(Net sale/income)					
- Chemicals	4323.78	3951.54	8225.93	24648.58	36729.04
- Drugs	5144.34	4141.87	6607.09	21092.56	27502.84
- Unallocated	47.65	138.12	58.62	256.89	311.30
<b>Total</b>	<b>9515.77</b>	<b>8231.53</b>	<b>14891.64</b>	<b>45998.03</b>	<b>64543.18</b>
Less: Inter segment revenue	1988.45	1435.70	1792.87	7395.64	8064.18
<b>Net sales/income from operations</b>	<b>7527.32</b>	<b>6795.83</b>	<b>13098.77</b>	<b>38602.39</b>	<b>56479.00</b>
<b>2. Segment Results</b>					
Profit(+)/(loss)(-) before tax and interest from each segment)					
- Chemicals	(1967.12)	(2010.33)	(233.76)	(5045.31)	71.69
- Drugs	314.38	79.84	1823.58	3182.53	6246.95
<b>Total</b>	<b>(1652.74)</b>	<b>(1930.49)</b>	<b>1589.82</b>	<b>(1862.78)</b>	<b>6318.64</b>
Less: Interest	1474.75	1406.55	1499.20	5910.54	6034.39
Less: Other un-allocable expenditure net of unallocable income	(33.80)	(127.49)	(7.17)	(229.52)	(223.98)
<b>Total Profit(+)/(loss) (-) before tax &amp; Extraordinary items</b>	<b>(3093.69)</b>	<b>(3209.55)</b>	<b>97.79</b>	<b>(7543.80)</b>	<b>508.23</b>
<b>3. Capital Employed</b>					
(Segment assets - Segment Liabilities)					
- Chemicals	8750.54	7749.65	10452.27	8750.54	10452.27
- Drugs	11040.72	14311.42	11349.49	11040.72	11349.49
- Unallocated	967.07	1847.93	337.13	967.07	337.13
<b>Total</b>	<b>20758.33</b>	<b>23909.00</b>	<b>22138.89</b>	<b>20758.33</b>	<b>22138.89</b>

### NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 29 May 2015.
- Consequent to the enactment of the Companies Act, 2013 (the Act) and its applicability for accounting periods commencing from 01 April 2014, the Company has recalculated the remaining useful life of fixed assets in accordance with provisions of Schedule II to the Act. In case of fixed assets which have already completed their useful life in terms of Schedule II of the Act, the carrying value (net of residual value) of such assets as at 01 April 2014 amounting to Rs.262.04 lacs (net of deferred tax Rs 117.18 lac) has been adjusted to retained earnings and in case of other fixed assets the carrying value (net of residual value) is being depreciated as per straight line method over the re-calculated remaining useful life. The depreciation and amortization expense charged for year ended 31 March 2015 would have been higher by Rs.229.17 lacs, had the company continued with the previously prescribed depreciation rates as per Schedule-XIV of Companies Act,1956.
- In May 2015 the Company has allotted 10,00,000 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the non promoters, on exercise of the option attached with warrants allotted on 04 July 2014. The paid up capital of the company increased from 4,76,55,502 equity shares of Rs10/- each to 4,86,55,502 equity shares of Rs 10/- each.
- During the year, FCCB's holders converted their US\$ 7 million Zero Coupon Unsecured Foreign Currency Convertible Bonds issued in May 2010 into equity shares capital, imposing faith in long term growth of Company
- During the year the chemical business of the company had not performed well due to various market forces which resulted into losses.
- Lender's have restructured the credit facilities along with additional exposure for debottlenecking project for Ibuprofen a flagship product by which the capacity of Ibuprofen will increase.
- The Company has received EDQM approval for its product Metformin. The Company has also EDQM certification for Ibuprofen and Lamotrigine with it. The Company is making efforts of moving towards Pharma, a higher growth business.
- Previous years figures have been regrouped/ reclassified/ rearranged wherever necessary. The figures of last quarter are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2015 and the published year to date figures upto the third quarter ended 31 December 2014



For IOL Chemicals and Pharmaceuticals Limited



Sd/-

Vijay Kumar Garg  
Joint Managing Director  
DIN: 06510248

Place: Ludhiana  
Date: 29 May 2015

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India

Ph. : +91-1679 -285285-86, Fax : +91-1679-285292